Explore HGH Fragment 176-191 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
HGH Fragment 176-191 is a stabilized form of the C-terminal region of human growth hormone, studied for its lipolytic activity without the growth-promoting effects of full-length hGH. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting this hGH-derived fat-targeting fragment.
HGH Fragment 176-191 is the unstabilized parent of AOD-9604, and the two molecules are best understood together. The C-terminal 16 amino acids of human growth hormone were characterized in the 1990s as the region of the molecule that retains hGH's lipolytic and anti-lipogenic activity while leaving behind the IGF-1-driven somatogenic effects that make full-length hGH a growth-promoting hormone — the work running through Wu et al. and Ng et al. on hGH 177-191's effect on adipocyte lipolysis. Metabolic Pharmaceuticals later took that fragment, added a tyrosine to the N-terminus to improve stability and shelf life, and developed it as AOD-9604 — which advanced into multiple Phase II obesity trials in the mid-2000s and ultimately failed to demonstrate weight-loss efficacy versus placebo at oral doses up to 30mg/day.
HGH Fragment 176-191 is the fat-mobilizing C-terminal fragment of human growth hormone, most often sourced for lipolysis and body-composition research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and is closely related to — but not identical to — the tyrosine-extended analog AOD-9604, which is the version that actually reached human trials.
Native growth hormone exerts its lipolytic effect through a distinct C-terminal domain that does not require IGF-1 or the classical JAK2/STAT5 cascade triggered by GH-receptor activation. HGH Fragment 176-191 retains this lipolytic activity in adipocyte assays while losing the anabolic, insulin-antagonist, and hyperglycemic effects of the full-length hormone — at least in animal models.
Pre-clinical work demonstrated reduced adipose mass, increased fat oxidation, and absence of hyperglycemia in obese rodent models. The tyrosine-extended analog (AOD-9604) reached a 12-week Phase 2b trial in obese adults (Heffernan / Ng programs), reporting modest weight loss vs. placebo before the program was halted. The non-tyrosylated 176-191 fragment itself has not been the subject of a published controlled human trial.
HGH Fragment 176-191 has a reported half-life of ~30 min, and the dose intervals researchers model most often fall around once or twice daily (fasted). Very short half-life — each dose is gone within a few hours with no buildup between days, so timing relative to fasting matters more than steady-state level. It is catalogued under Weight Loss on WPA.
185 HGH Fragment 176-191 reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (40 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (40 sessions). The most common dosing frequency is daily (7x/week) (13 logged protocols), followed by once weekly (3).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.